The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1440-1451

  Sonabend, Adam M ^a   Bansal, Mukesh ^c,e   Guarnieri, Paolo ^c,e   Lei, Liang ^a   Amendolara, Benjamin ^a   Soderquist, Craig ^a   Leung, Richard ^a   Yun, Jonathan ^a   Kennedy, Benjamin ^a   Sisti, Julia ^a   Bruce, Samuel ^a   Bruce, Rachel ^a   Shakya, Reena ^g   Ludwig, Thomas ^g   Rosenfeld, Steven ^h   Sims, Peter A ^b,c   Bruce, Jeffrey N ^a   Califano, Andrea ^a,b,c,d,e,f   Canoll, Peter ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Departments of Systems Biology   (United States)

^d Department of Civil Environmental and Geodetic Engineering Electrical and Computer Engineering Biomedical Informatics and Neuroscience   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f Institute for Cancer Genetics   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; GENE DELETION; GENE EXPRESSION; GENOTYPE PHENOTYPE CORRELATION; GLIOMA; HUMAN VERSUS ANIMAL COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLIOMA; HUMANS; MICE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896510486     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2150     Document Type: Article

References (44)

1. Network. CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455: 1061-8.
2. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
3. Zong H, Verhaak RG, Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn 2012; 12:383-94.
4. LaFramboise T, Dewal N, Wilkins K, Pe'er I, Freedman ML. Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. PLoS Genet 2010;6:e1001086.
5. Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier ME, Dutrillaux B, et al. Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther 2006; 5:2182-92.
6. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986;46:5125-30.
7. Dworkin AM, Ridd K, Bautista D, Allain DC, Iwenofu OH, Roy R, et al. Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet 2010;6:e1001136.
8. Gatenby RA, Brown J, Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 2009; 69:7499-502.
9. Jonsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005;65:7612-21.
10. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006;313:521-2.
11. O'Regan EM, Toner ME, Smyth PC, Finn SP, Timon C, Cahill S, et al. Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. Head Neck 2006; 28:330-8.
12. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.
13. Lei L, Sonabend AM, Guarnieri P, Soderquist C, Ludwig T, Rosenfeld S, et al. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PloS ONE 2011;6:e20041.
14. Verhaak RG, Hoadley KA, Purdom E,WangV, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
15. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008;1:52.
16. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PloS ONE 2010;5:e12548.
17. Besnard F, Perraud F, Sensenbrenner M, Labourdette G. Plateletderived growth factor is a mitogen for glial but not for neuronal rat brain cells in vitro. Neurosci Lett 1987;73:287-92.
18. Westermark B, Wasteson A.Aplatelet factor stimulatinghuman normal glial cells. Exp Cell Res 1976;98:170-4.
19. Huse JT, Holland E, DeAngelis LM. Glioblastoma: molecular analysis and clinical implications. Annu Rev Med 2013;64:59-70.
20. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 2009;4:e7752.
21. Gensert JM, Goldman JE. Heterogeneity of cycling glial progenitors in the adult mammalian cortex and white matter. J Neurobiol 2001;48: 75-86.
22. Mason JL, Goldman JE. A2B5+ and O4+ Cycling progenitors in the adult forebrain white matter respond differentially to PDGF-AA, FGF-2, and IGF-1. Mol Cell Neurosci 2002;20:30-42.
23. Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 1996;17:229-43.
24. Sonabend AM, Yun J, Lei L, Leung R, Soderquist C, Crisman C, et al. Murine cell line model of proneural glioma for evaluation of anti-Tumor therapies. J Neurooncol 2013;112:375-82.
25. Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, et al.AhumanB-cell interactome identifiesMYBandFOXM1as master regulators of proliferation in germinal centers. Mol Syst Biol 2010; 6:377.
26. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M. Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas. J Cancer Res Clin Oncol 2001;127:325-8.
27. Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 2005;42:68-77.
28. Hu J, Pang JC, Tong CY, Lau B, Yin XL, Poon WS, et al. High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours. Br J Cancer 2002;87:218-24.
29. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011;333:1453-5.
30. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17: 510-22.
31. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008;7:41.
32. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008;28:264-78.
33. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011;146:209-21.
34. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
35. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9.
36. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
37. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455:1129-33.
38. Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011; 19:305-16.
39. Andrysik Z, Kim J, Tan AC, Espinosa JM. A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation. Cell Rep 2013;3:1346-54.
40. Kim S, Chung AY, Kim D, Kim YS, Kim HS, Kwon HW, et al. Tcf3 function is required for the inhibition of oligodendroglial fate specification in the spinal cord of zebrafish embryos. Mol Cells 2011;32: 383-8.
41. He Y, Dupree J, Wang J, Sandoval J, Li J, Liu H, et al. The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 2007;55:217-30.
42. Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, et al. Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol 2012;8:605.
43. Pitter KL, Galban CJ, Galban S, Tehrani OS, Li F, Charles N, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE 2011;6:e14545.
44. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887.